Status:
UNKNOWN
Voriconazole for IPA in Chinese Patients With COPD
Lead Sponsor:
Red Cross Hospital, Hangzhou, China
Collaborating Sponsors:
Sir Run Run Shaw Hospital
Zhejiang Provincial People's Hospital
Conditions:
Invasive Pulmonary Aspergillosis
COPD
Eligibility:
All Genders
30-85 years
Phase:
PHASE4
Brief Summary
voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD ...
Detailed Description
This is a multiple-center open-label clinical trial to study the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD in Chinese patients.The primary end...
Eligibility Criteria
Inclusion
- Cases of invasive pulmonary aspergillosis secondary to COPD
Exclusion
- Use of voriconazole or itraconazole or amphotericin B or caspofungin or micafungin within 4 weeks prior to enrollment
- Known allergy to voriconazole
- Severe impairment of live or kidney function
- Septic shock
- Unwilling to sign informed consent
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02234739
Start Date
October 1 2014
End Date
December 1 2016
Last Update
September 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hangzhou Red Cross Hospital
Hangzhou, Zhejiang, China, 310003